W

Lilly’s revenue soars 48%, driven by demand for its GLP-1s

商业管理
分享到
Lilly’s revenue soars 48%, driven by demand for its GLP-1s

Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

Lilly’s revenue soars 48%, driven by demand for its GLP-1s

Source：MarketWatch

友情提醒：请广大读者理性看待市场信息，切实提高风险意识。站内所有内容仅系市场信息或相关方观点，不构成任何形式投资建议。

延伸阅读

Solana’s 150-millisecond settlement upgrade reaches second public test network

Alpenglow is running on both public test networks, giving application teams a place to check their software before the live blockchain switches. Source：CoinDesk

XRP Ledger’s Batch upgrade slips to Oct. 9 after validator support resets

The feature would let users bundle up to eight transactions, including assetandpayment transfers, but a brief drop below the network’s 80% support threshold…

Bitcoin could soon get Zcash-style 'shielded' privacy without changing its rules

Researchers have mapped out private bitcoindenominated transfers that run alongside Bitcoin, but the system still lacks a finished way to lock up real BTC and…

U.S. SEC's steadiest crypto advocate, Hester Peirce, to depart next week

The longanticipated exit of the commissioner sometimes known as Crypto Mom is Oct. 2, announced as the agency was sending out its latest crypto work.…

来源：https://www.marketwatch.com/story/lillys-revenue-soars-48-driven-by-demand-of-its-glp-1s-7361c223